GAINESVILLE & BOCA RATON, FL. – The Institute for Commercialization of Public Research (the Institute) announced today that it has finalized a funding agreement with Gainesville-based TruVitals, developers of technology that enables remote, stationary and portable monitoring of heartbeat and respiration in humans and animals. The Institute works with Florida’s research universities and institutions to support new company creation and job growth, bridging early funding gaps and enabling them to attract additional private investment capital.
“The Institute is committed to building and funding the next generation of innovation-based companies in Florida, and TruVitals is well on its way to having a major impact on how this aspect of healthcare is delivered”
TruVitals, Inc. is committed to improving the quality of patient care worldwide with its sensor system that continuously monitors human and animal vital signs with zero-contactTM, which means no sensors are attached or used to detect the patients’ vital signs. It improves quality of care by alerting caregivers of changes to patients’ heartbeat, respiration, and movement such as from coughing or shaking.
“Our system will transmit patient data wirelessly and securely over the cloud where it can be reviewed by a caregiver’s portable device, anytime and anywhere,” said Bob Herbolich, TruVitals CEO. Vital signs associated with pain and stress can be detected in real-time such as in post-op and recovery, or during the onset of illness or when injury is about to occur. We envision caregivers will have a new tool to help minimize patient pain, suffering and significantly improve the quality of care while lowering its overall cost.
“The Institute is committed to building and funding the next generation of innovation-based companies in Florida, and TruVitals is well on its way to having a major impact on how this aspect of healthcare is delivered,” said Jamie Grooms, CEO of the Institute. “By minimizing patient contact without compromising care, the TruVitals device will reduce infections and other adverse effects of hospitalization, which will ultimately result in cost savings and improved patient outcomes for both humans and animals.”